Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HMBS | P08397 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19221617 | 0.84 | ALDH1A1 (0.31) | DAOALDH1A1HPGD | |
| SCHEMBL12071844 | 0.82 | NPC1 (0.31) | MAPT | |
| SCHEMBL21718510 | 0.80 | — | — | |
| SCHEMBL2756557 | 0.76 | BCHE (0.32) | BCHEACHEGABRA1GABRB2 | |
| SCHEMBL10262151 | 0.76 | ALDH1A1 (0.32) | ALDH1A1HPGD | |
| SCHEMBL14791094 | 0.74 | — | — | |
| SCHEMBL7616986 | 0.74 | HIF1A (0.39) | DAOALDH1A1MAPT | |
| SCHEMBL15043728 | 0.74 | DAO (0.39) | DAOALDH1A1HPGDTSHRLMNA | |
| SCHEMBL15829387 | 0.74 | LOXL2 (0.33) | — | |
| SCHEMBL11365710 | 0.69 | MEN1 (0.38) | DAOALDH1A1HPGDTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113754694-A | Method for synthesizing Reidesvir by asymmetric catalysis of non-protecting group nucleoside | 上海交通大学 | 2021-12-07 | — | — | CN | claimed |
| EP-4737461-A1 | NOVEL COMPOUND, PRECURSOR COMPOSITION COMPRISING SAME, AND METHOD FOR MANUFACTURING THIN FILM USING SAME | Hansol Chemical Co., Ltd (KR) | 2026-05-06 | — | — | EP | disclosed |
| WO-2025005677-A1 | NOVEL COMPOUND, PRECURSOR COMPOSITION COMPRISING SAME, AND METHOD FOR MANUFACTURING THIN FILM USING SAME | 주식회사 한솔케미칼 | 2025-01-02 | — | — | WO | disclosed |
| CN-115246759-B | Method for preparing hexene and co-producing octene and decene by oligomerization | 中国石油天然气股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20230339971-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20080027377-A1 | Catheters having actuatable lumen assemblies | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080012010-A1 | ORGANIC ELECTRONIC DEVICE, METHOD FOR PRODUCTION THEREOF, AND ORGANIC SEMICONDUCTOR MOLECULE | SONY CORPORATION (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070082892-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-20070066819-A1 | PROCESS FOR THE PREPARATION OF BENZOTRIAZEPINE DERIVATIVES | JANSSEN PHARMACUETICA N.V., (BE) | 2007-03-22 | — | — | US | disclosed |
| CN-1142192-C | Catalyst system containing reaction product of liquid cilicone and polyamine | 伊奎斯塔化学有限公司 | 2004-03-17 | — | — | CN | disclosed |
| EP-0741145-B1 | Olefin polymerization catalyst and process for producing polyolefin using the same | SUMITOMO CHEMICAL CO (JP) | 1999-12-29 | — | — | EP | disclosed |
| CN-1220671-A | Catalyst system comprising the reaction product of a liquid silicone and a polyamine | EQUISTA CHEMICAL CO LTD (US) | 1999-06-23 | — | — | CN | disclosed |
| CN-1145370-A | Olefin polymerization catalyst and process for producing polyolefin using the same | SUMITOMO CHEMICAL CO (JP) | 1997-03-19 | — | — | CN | disclosed |
| EP-0741145-A1 | Olefin polymerization catalyst and process for producing polyolefin using the same | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066819-A1 | PROCESS FOR THE PREPARATION OF BENZOTRIAZEPINE DERIVATIVES | CCKBR, CCKAR, GRPR | DAO 1373/4885ALDH1A1 3751/4885HPGD 2087/4885 |
| US-20230339971-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | SDHA, SDHB, DHFR | DAO 1528/4885ALDH1A1 840/4885HPGD 291/4885 |
| US-20070082892-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | DAO 1450/4885ALDH1A1 2440/4885HPGD 866/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | DAO 4084/4885ALDH1A1 4157/4885HPGD 4393/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | DAO 1630/4885ALDH1A1 1427/4885HPGD 3064/4885 |
| US-20070185093-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | DAO 1450/4885ALDH1A1 2440/4885HPGD 866/4885 |
| US-12024528-B2 | Bridged tricyclic carbamoylpyridone compounds and uses thereof | SDHA, SDHB, DPYD | DAO 1443/4885ALDH1A1 684/4885HPGD 264/4885 |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | DAO 3538/4885ALDH1A1 2512/4885HPGD 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.